Rituximab for refractory Wegener's granulomatosis

被引：2

作者：

Antonin, Sabina A. ^{[1
]}

机构：

[1] Clin Pulm Dis, Iasi 700115, Romania

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2006年 / 15卷 / 09期

关键词：

ANCA; anti-CD20; antibodies; refractory Wegener's granulomatosis; rituximab;

D O I：

10.1517/13543784.15.9.1115

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Wegener's granulomatosis is a rapidly progressing small vessel vasculitis involving mainly the lungs and kidneys and has antineutrophil cytoplasm antibodies against protease 3 as a common immunological marker. Therapy is aimed at prolonging survival, inducing remission of the active disease and preventing its relapse. Several immunosuppressive agents are currently used in conventional regimen, and cyclophosphamide is the most commonly used. In patients refractory to such therapies, other drugs have to be used and rituximab (an antibody against CD20(+) cells) could be a potentially effective treatment for this subset. The data on its clinical efficacy are only preliminary and further studies are needed.

引用

收藏

页码：1115 / 1117

页数：3

相关论文

共 16 条

[1] Efficacy of the anti-TNF-α antibody infliximab against refractory systemic vasculitides:: an open pilot study on 10 patients [J].

Bartolucci, P ;

Ramanoelina, J ;

Cohen, P ;

Mahr, A ;

Godmer, P ;

Le Hello, C ;

Guillevin, L .

RHEUMATOLOGY, 2002, 41 (10) :1126-1132

[2] 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis:: A six-month open-label trial to evaluate safety and efficacy [J].

Birck, R ;

Warnatz, K ;

Lorenz, HM ;

Choi, M ;

Haubitz, M ;

Grünke, M ;

Peter, HH ;

Kalden, JR ;

Göbel, U ;

Drexler, JM ;

Hotta, O ;

Nowack, R ;

Van der Woude, FJ .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (02) :440-447

[3] The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review [J].

de Groot, K ;

Adu, D ;

Savage, COS .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 (10) :2018-2027

[4] Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab [J].

Eriksson, P .

JOURNAL OF INTERNAL MEDICINE, 2005, 257 (06) :540-548

[5] Rituximab for refractory Wegener's granulomatosis - Report of a prospective, open-label pilot trial [J].

Keogh, KA ;

Ytterberg, SR ;

Fervenza, FC ;

Carlson, KA ;

Schroeder, DR ;

Specks, U .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2006, 173 (02) :180-187

[6] Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis [J].

Keogh, KA ;

Wylam, ME ;

Stone, JH ;

Specks, U .

ARTHRITIS AND RHEUMATISM, 2005, 52 (01) :262-268

[7] Wegener's granulomatosis: current and upcoming therapies [J].

Langford, CA .

ARTHRITIS RESEARCH & THERAPY, 2003, 5 (04) :180-191

[8] Prolonged treatment of refractory Wegener's granulomatosis with 15-deoxyspergualin:: an open study in seven patients [J].

Schmitt, WH ;

Birck, R ;

Heinzel, PA ;

Göbel, U ;

Choi, M ;

Warnatz, K ;

Peter, HH ;

van der Woude, FJ .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 (06) :1083-1092

[9] Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG):: An open study in 15 patients [J].

Schmitt, WH ;

Hagen, EC ;

Neumann, I ;

Nowack, R ;

Flores-Suárez, LF ;

van der Woude, FJ .

KIDNEY INTERNATIONAL, 2004, 65 (04) :1440-1448

[10] Rituximab and Wegener's granulomatosis: Are B cells a target in vasculitis treatment? [J].

Sneller, MC .

ARTHRITIS AND RHEUMATISM, 2005, 52 (01) :1-5